Integris Medtech Limited
About Integris Medtech Limited
Data last updated: 12 December 2025
Integris Medtech Limited is a public limited company based in New Delhi, Delhi, India, a subsidiary of Evercure Holding Pte Ltd. It specialises in medical equipment retail and distribution, a part of the broader healthcare sector. Incorporated on 25 April 2008, the company has been in operation for over 18 years.
Registered with ROC Delhi under CIN U85110DL2008PTC177230.
Capital: an authorised share capital of ₹157 Cr and a paid-up capital of ₹10.83 Cr. It is led by directors including Arjun Oberoi and Rajani Kesari.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: 1St Floor Metro Tower Lsc M.O.R Land New Rajinder Nagar, New Delhi, Delhi, India – 110060.
As per the financials filed for FY 2025, the company reported a revenue of ₹1,959.58 Cr, reflecting significant growth compared to the previous year.
It operates as a subsidiary of Evercure Holding Pte Ltd. Its group structure includes 2 subsidiaries.
The company is associated with 1 brand - Translumina. As per MCA filings, the company has open charges of ₹268 Cr and satisfied charges of ₹4 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website**************
-
Social Media**************
-
Registered Address1St Floor Metro Tower Lsc M.O.R Land New Rajinder Nagar, New Delhi, Delhi, India – 110060
-
IndustryHealthcare, Medical Equipment Retail & Distribution
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Integris Medtech Limited
Integris Medtech Limited has one previous CIN (Corporate Identification Number): U85110DL2008PTC177230. The current CIN is U85110DL2008PLC177230, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U85110DL2008PLC177230 | Current |
| U85110DL2008PTC177230 | Previous |
Associated Brands with Integris Medtech Limited
Integris Medtech Limited operates one associated brand: Translumina. These brands represent Integris Medtech Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of drug-eluting stents and cardiovascular devices. It produces drug-eluting stents, drug-eluting balloons, coronary balloons, and vascular accessories. The company operates advanced manufacturing facilities and is committed to delivering high-quality products. Its focus is on developing and providing innovative cardiovascular intervention technologies. The manufacturing processes adhere to rigorous international standards. | translumina.com |
Competitors & Alternatives of Integris Medtech Limited
Brands and companies operating in the same space as Integris Medtech Limited include SMT, InspireMD, Endospan and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
SMT
|
SMT is recognized as a developer of cardiovascular medical devices. | Surat, India, India | 1998 |
InspireMD
|
Proprietary stent systems with bio-stable mesh are developed and commercialized. | Boston, United States, United States | 2005 |
Endospan
|
Endovascular stent graft systems for aortic aneurysm repair are developed. | Herzliya, Israel, Israel | 2009 |
Vesper Medical
|
Venous stent system is developed for deep vein disease treatment. | Wayne, United States, United States | 2016 |
STENTiT
|
Developer of regenerative stent for vascular disorders | Eindhoven, Netherlands, Netherlands | 2007 |
Veryan Medical
|
Three-dimensional vascular stents for peripheral vascular disease are developed. | Horsham, United Kingdom, United Kingdom | 2003 |
Biosensors International
|
Products for interventional cardiology and critical care procedures | Singapore, Singapore, Singapore | 1990 |
Huamai Tyco
|
Abdominal aortic stent systems are developed for disease treatment. | Beijing, China, China | 2011 |
Lombard Medical
|
Endovascular stent grafts are developed, manufactured, and marketed. | Irvine, United States, United States | 2000 |
Business Activity of Integris Medtech Limited
Integris Medtech Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Integris Medtech Limited
Integris Medtech Limited is audited by Walker Chandiok & Co LLP for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Walker Chandiok & Co LLP | blur-value | blur-value | blur-value |
Board of Directors of Integris Medtech Limited
Integris Medtech Limited is currently managed by 12 directors, with 11 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Arjun Oberoi | Nominee Director | 21 Jul 2025 | 0 Years 11 Months | Current |
| Rajani Kesari | Director | 01 Aug 2025 | 0 Years 11 Months | Current |
|
Hemant Sultania
Also directs:
Orophilos Advisers Llp, Samavesh Ventues And Advisory Llp, Nephrocare Health Services Limited and 4 more
|
Cfo | 25 Aug 2025 | 0 Years 10 Months | Current |
|
Gurmit Singh Chugh
Also directs:
Pathway Medical Llp, Advance Therapeutics Llp, Halemed Medical Private Limited and 5 more
|
Director | 25 Apr 2008 | 18 Years 2 Months | Current |
| Darpan Batra | Company Secretary | 26 Sep 2025 | 0 Years 9 Months | Current |
|
Annaswamy Vaidheesh
Also directs:
North Star Asia Llp, Universal Nutriscience Private Limited, Appasamy Associates Private Limited and 1 more
|
Director | 26 Aug 2025 | 0 Years 10 Months | Current |
Financials of Integris Medtech Limited FY 2024 filings available
Integris Medtech Limited reported revenue of ₹1,959.58 Cr (up 239% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Integris Medtech Limited
As of FY 2024, Integris Medtech Limited's shareholding pattern shows 40.00% by promoters, 60.00% by public shareholders. Public shareholders hold the majority stake, reflecting broad public ownership.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Integris Medtech Limited
Integris Medtech Limited has 2 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Integris Medtech Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Transvalve Health Private Limited | U33100DL2021PTC389727 |
**.**%
|
| Transhealth Private Limited | U33309DL2020PTC364238 |
**.**%
|
Showing major subsidiaries. Total: 2.
Charges & Borrowings of Integris Medtech Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Oct 2025 | Hdfc Bank Limited | ₹60 Cr | Open |
| 01 Oct 2025 | Hdfc Bank Limited | ₹17 Cr | Open |
| 03 May 2023 | Hdfc Bank Limited | ₹140 Cr | Open |
| 06 Mar 2023 | Others | ₹2 Cr | Open |
| 02 Mar 2022 | Citi Bank N.A. | ₹17 Cr | Open |
Total charge records: 9 View all charges
Employees and EPFO Compliance at Integris Medtech Limited
View historical data on people associated with Integris Medtech Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Integris Medtech Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Integris Medtech Limited
GSTIN & GST Filing Data of Integris Medtech Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Integris Medtech Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Integris Medtech Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Integris Medtech Limited
MSME Payment Delays by Integris Medtech Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Integris Medtech Limited
Subsidiaries & Group Companies of Integris Medtech Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Integris Medtech Limited with ownership details.
MCA Filings & Documents of Integris Medtech Limited
MCA Filings & Documents of Integris Medtech Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Integris Medtech Limited
Frequently Asked Questions about Integris Medtech Limited
Integris Medtech Limited is an active public limited company in the healthcare sector based in New Delhi, Delhi, India. It was incorporated on 25 April 2008 (18+ years old) and is registered under CIN U85110DL2008PLC177230.
Integris Medtech Limited reported revenue of ₹1,959.58 Cr for FY 2025 (up 239.00% YoY).
The current directors of Integris Medtech Limited are:
The primary industry of Integris Medtech Limited is healthcare. The company specifically operates in medical equipment retail and distribution. The company is currently active in this sector.
Integris Medtech Limited can be reached at the registered office: 1St Floor Metro Tower Lsc M.O.R Land New Rajinder Nagar, New Delhi, Delhi, India – 110060.
The authorised capital is ₹157 Cr, and the paid-up capital is ₹10.83 Cr.